# ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Source: https://onco.cc/trials/nct05601752/  
OnCo record `nct05601752` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab in ovarian cancer, run by USWM CT, LLC, stopped early.

## Summary

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) is a phase 2 interventional study registered as NCT05601752 by USWM CT, LLC, with 66 participants planned, started 2023-06-26 and reached its primary completion in 2025-09-30. Interventions recorded: Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-19
- Also known as: SURPASS-3
- Tags: ctgov-ingest
- Registry id: NCT05601752
- Phase: 2
- Setting: A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
- Sponsor: USWM CT, LLC
- Enrolled: 66

## Notes

- Registry status on 19 October 2026: Terminated (registry record last updated 19 October 2026; primary completion reached 30 September 2025). Why stopped, in the sponsor's words: Enrollment was halted following withdrawal of the U.S. IND. Previously enrolled participants completed treatment and follow-up, after which the study was closed.

## Sources

- ClinicalTrials.gov NCT05601752: https://clinicaltrials.gov/study/NCT05601752

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05601752.json